Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announced grant of five patents covering the Company’s IL-2 and IL-4 Superkine platforms. These patents strengthen Medicenna’s intellectual property (IP) position across key markets and further support the Company’s lead clinical and preclinical programs.

Read more at globenewswire.com